Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Investment analysts at Roth Capital dropped their Q2 2025 earnings estimates for Sensus Healthcare in a research note issued to investors on Thursday, May 15th. Roth Capital analyst J. Wittes now expects that the company will post earnings of $0.03 per share for the quarter, down from their prior forecast of $0.08. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.32 per share. Roth Capital also issued estimates for Sensus Healthcare's Q4 2025 earnings at $0.18 EPS, FY2026 earnings at $0.19 EPS and FY2027 earnings at $0.22 EPS.
Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The company had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million.
A number of other equities research analysts have also recently issued reports on SRTS. Lake Street Capital reduced their target price on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Sensus Healthcare in a research report on Friday, April 4th.
View Our Latest Report on Sensus Healthcare
Sensus Healthcare Stock Performance
Shares of Sensus Healthcare stock opened at $4.46 on Monday. The firm has a 50-day moving average of $4.61 and a 200-day moving average of $6.12. The stock has a market cap of $73.57 million, a PE ratio of 11.15 and a beta of 1.30. Sensus Healthcare has a 52-week low of $4.01 and a 52-week high of $9.33.
Institutional Investors Weigh In On Sensus Healthcare
Several institutional investors and hedge funds have recently bought and sold shares of the company. Trexquant Investment LP acquired a new position in Sensus Healthcare during the first quarter worth about $93,000. Meros Investment Management LP bought a new stake in Sensus Healthcare in the first quarter valued at approximately $419,000. American Century Companies Inc. boosted its holdings in Sensus Healthcare by 12.7% in the first quarter. American Century Companies Inc. now owns 22,440 shares of the company's stock valued at $106,000 after acquiring an additional 2,520 shares during the last quarter. Pacific Ridge Capital Partners LLC bought a new stake in Sensus Healthcare in the first quarter valued at approximately $542,000. Finally, IFP Advisors Inc grew its position in shares of Sensus Healthcare by 37.2% during the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock worth $89,000 after buying an additional 5,100 shares during the period. Institutional investors own 25.30% of the company's stock.
About Sensus Healthcare
(
Get Free Report)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sensus Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sensus Healthcare wasn't on the list.
While Sensus Healthcare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
